Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000177640 | SCV000229541 | uncertain significance | not provided | 2016-02-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000177640 | SCV003231954 | benign | not provided | 2024-12-12 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000177640 | SCV003828163 | likely benign | not provided | 2023-12-12 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000177640 | SCV005192219 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Gene |
RCV000177640 | SCV005441415 | uncertain significance | not provided | 2024-06-27 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Occurs in the triple helical domain at the Y position in the canonical Gly-X-Y repeat; although this variant may have an effect on normal protein folding and function, missense substitution at the Y position is not a common mechanism of disease; In silico analysis indicates that this missense variant does not alter protein structure/function |
Prevention |
RCV004539653 | SCV004783369 | likely benign | COL4A1-related disorder | 2022-09-26 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |